State Street Corp Has $19.64 Million Stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

State Street Corp lowered its holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 8.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,013,083 shares of the company’s stock after selling 655,041 shares during the quarter. State Street Corp’s holdings in Allogene Therapeutics were worth $19,637,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Nisa Investment Advisors LLC lifted its stake in shares of Allogene Therapeutics by 429.6% in the second quarter. Nisa Investment Advisors LLC now owns 10,767 shares of the company’s stock valued at $25,000 after buying an additional 8,734 shares in the last quarter. Federated Hermes Inc. bought a new position in Allogene Therapeutics in the 2nd quarter valued at about $29,000. Private Advisor Group LLC acquired a new position in Allogene Therapeutics during the 3rd quarter valued at about $34,000. Algert Global LLC bought a new stake in Allogene Therapeutics during the 2nd quarter worth approximately $35,000. Finally, Rothschild Investment LLC purchased a new stake in shares of Allogene Therapeutics in the second quarter worth approximately $52,000. Institutional investors own 83.63% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on ALLO shares. HC Wainwright reiterated a “buy” rating and set a $9.00 price target on shares of Allogene Therapeutics in a report on Friday, November 8th. William Blair reiterated an “outperform” rating on shares of Allogene Therapeutics in a research note on Thursday, November 14th. Finally, Piper Sandler dropped their price target on shares of Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating on the stock in a research report on Thursday, November 14th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $9.73.

Allogene Therapeutics Stock Up 4.3 %

Shares of ALLO stock opened at $1.95 on Tuesday. The firm has a market cap of $408.86 million, a P/E ratio of -1.25 and a beta of 0.83. The company has a 50 day moving average of $2.48 and a 200-day moving average of $2.56. Allogene Therapeutics, Inc. has a 12-month low of $1.78 and a 12-month high of $5.78.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).